Fetal Alcohol Syndrome

National Organization for Rare Disorders, Inc.

Skip to the navigation


It is possible that the main title of the report Fetal Alcohol Syndrome is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.


  • Alcohol-Related Birth Defects
  • Alcoholic Embryopathy
  • FAS
  • Alcohol, Fetal Effects of

Disorder Subdivisions

  • None

General Discussion

Fetal alcohol syndrome (FAS) is a characteristic pattern of mental and physical birth defects that results due to maternal use of alcohol during pregnancy. The range and severity of associated abnormalities may vary greatly from case to case. However, characteristic features may include growth delays before and after birth (prenatal and postnatal growth retardation); malformations of the skull and facial (craniofacial) region; brain abnormalities; and/or additional physical findings. FAS may also be associated with varying degrees of mental retardation, learning abnormalities, and/or behavioral problems that, in some cases, may occur in the absence of obvious physical abnormalities.


Prenatal exposure to alcohol may have multiple effects, including miscarriage, growth deficiencies, intellectual impairment, or the specific pattern of malformations at the severe end of the spectrum known as fetal alcohol syndrome (FAS). More mildly affected infants and children may be said to manifest fetal alcohol effects (FAE).

The symptoms and findings associated with FAS may vary from case to case. However, characteristic features often include prenatal and/or postnatal growth retardation, resulting in low weight and height. Many affected newborns may also have increased irritability, an increased sensitivity to sounds (hyperacusis), abnormal muscle tone, and fine motor dysfunction, including tremulousness, a weak grasp, and poor hand-eye coordination.

Evidence indicates that FAS is a leading cause of mental retardation. The degree of intellectual impairment may vary from mild to severe. The term "microcephaly" indicates that the head circumference is smaller than would be expected for age and sex. Microcephaly is a common feature of FAS that is thought to be due to an overall decrease in brain growth. In addition, specific brain abnormalities have been reported in association with FAS, including absence of the band of nerve fibers that joins the cerebral hemispheres (corpus callosum) and underdevelopment of a region of the brain involved in coordinating voluntary movement (cerebellar hypoplasia).

Children with FAS commonly have deficits in learning skills, difficulties with problem solving and memory, and/or speech impairment. In addition, many have certain behavioral abnormalities, including hyperactivity, impaired judgment, easy distractibility, impulsiveness, and impaired social and adaptive behaviors. In some cases, such abnormalities may be present in the apparent absence of physical anomalies.

FAS may also be associated with certain facial features, such as short eyelid folds (palpebral fissures); vertical skin folds that may cover the eyes' inner corners (epicanthal folds); and/or a short, upturned nose with a broad nasal bridge. Additional characteristic features may include a thin upper lip; an abnormally long, smooth vertical groove (philtrum) in the center of the upper lip; a small jaw (micrognathia); and/or flattened mid-facial regions (midfacial hypoplasia). Eye abnormalities may also be present, such as unusually small eyes (microphthalmia), drooping of the upper eyelids (ptosis), and/or abnormal deviation of one eye in relation to the other (strabismus). Reports indicate that associated facial features may sometimes be relatively subtle; in addition, they may tend to become less apparent as a child reaches puberty.

In some cases, various heart defects may also be present, particularly an abnormal opening in the partition between the lower or upper chambers of the heart (ventricular or atrial septal defects). Affected infants may also have joint abnormalities, including abnormal positioning and/or decreased range of motion. Additional physical abnormalities have also been reported in some individuals with the syndrome.


Maternal alcohol use during pregnancy can result in multiple effects on the developing embryo and fetus, including fetal alcohol syndrome (FAS). The specific amount of alcohol ingestion that may cause FAS has not been determined. However, evidence suggests that moderate and high levels of alcohol consumption during pregnancy can disrupt normal fetal growth and development. Some researchers indicate that heavy drinking throughout pregnancy may lead to more severe, wide ranging abnormalities characteristic of FAS, while occasional binge drinking at high levels may result in certain FAS features, with the specific defects dependent on the time of fetal exposure.

It is not known whether the adverse effects of alcohol during fetal development may be due to the alcohol itself or one of its by-products. In addition, the potential contributing role of other factors remains unclear, such as genetic influences affecting alcohol metabolism or additional environmental factors (e.g., maternal tobacco use). Some investigators suggest that alcohol use may impair the transfer of certain essential nutrients via the placenta, playing some role in the prenatal growth retardation characteristic of the syndrome.

Because the amount of alcohol necessary to cause FAS is unknown, it is recommended that pregnant women abstain from drinking alcohol.

Affected Populations

Researchers estimate that fetal alcohol syndrome (FAS) occurs in approximately one to two in 1,000 live births in the United States. According to reports in the medical literature, FAS is considered the primary cause of mental retardation in the Western world.

Standard Therapies

Treatment of FAS is generally symptomatic and supportive. Early intervention is important in enabling affected children to reach their potential. Special services that may be beneficial include special education, speech therapy, physical therapy, and/or other medical, social, and/or vocational services.

Prevention of FAS is achieved by abstaining from alcohol use during pregnancy.

Investigational Therapies

Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. Government funding, and some supported by private industry, are posted on this government web site.

For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:

Tollfree: (800) 411-1222

TTY: (866) 411-1010

Email: prpl@cc.nih.gov

For information about clinical trials sponsored by private sources, contact:




Behrman RE, ed. Nelson Textbook of Pediatrics, 16th ed. Philadelphia, Pa: W.B. Saunders Company; 2000:531.

Stratton KC Howe, and F. Battaglia, eds. Fetal Alcohol Syndrome: Diagnosis, Epidemiology, Prevention, and Treatment. Washington, DC:National Academy Press; 1996.

Beers MH, et al., eds. The Merck Manual. 17th ed. Whitehouse Station, NJ: Merck Research Laboratories; 1999:2035, 2158.

Adams RD, et al., eds. Principles of Neurology. 6th ed. New York, NY: McGraw-Hill, Companies; 1997:1180-81.

Jones KL, ed. Smith's Recognizable Patterns of Human Malformation. 5th ed. Philadelphia, PA: W. B. Saunders Co: 1997:4, 555-58.

Menkes JH, au., Pine JW, et al., eds. Textbook of Child Neurology, 5th ed. Baltimore, MD: Williams & Wilkins; 1995:604-05.

Buyce ML, ed. Birth Defects Encyclopedia. Dover, MA: Blackwell Scientific Pubs; For: The Center for Birth Defects Information Services Inc; 1990:684-85.

Gorlin RJ, et al., eds. Syndromes of the Head and Neck, 3rd ed. New York, NY: Oxford University Press; 1990:16-17.


Randall CL. Alcohol and pregnancy: highlights from three decades of research. J Stud Alcohol. 2001;62:554-61.

Whaley SE, et al. Comparison of the adaptive functioning of children prenatally exposed to alcohol to a nonexposed clinical sample. Alcohol Clin Exp Res. 2001;25:1018-24.

Kaskutas LA, et al. Pre-pregnancy drinking: how drink size affects risk assessment. Addiction. 2001;96:1199-209.

Ikonomidou C, et al. Ethanol-induced apoptotic neurodegeneration and fetal alcohol syndrome. Science. 2000;287:1056-60.

Mattson SN, et al. Parent ratings of behavior in children with heavy prenatal alcohol exposure and IQ-matched controls. Alcohol Clin Exp Res. 2000;24:226-31.

Mattson SN, et al. Executive functioning in children with heavy prenatal alcohol exposure. Alcohol Clin Exp Res. 1999;23:1808-15.

Ebrahim SH, et al. Comparison of binge drinking among pregnant and nonpregnant women, United States, 1991-1995. Am J Obstet Gynecol. 1999;180:1-7.

Murphy-Brennan MG, et al. Is there evidence to show that fetal alcohol syndrome can be prevented? J Drug Educ. 1999;29:5-24.

Ebrahim SH, et al. Alcohol consumption by pregnant women in the United States during 1988-1995. Obstet Gynecol. 1998;92:187-92.

Olson HC, et al. Neurophsychological deficits in adolescents with fetal alcohol syndrome: clinical findings. Alcohol Clin Exp Res. 1998;22:1998-2012.

Roebuck TM, et al. Neuromuscular responses to disturbance of balance in children with prenatal exposure to alcohol. Alcohol Clin Exp Res. 1998;22:1992-97.

Swayne VW. Magnetic resonance imaging of brain anomalies in fetal alcohol syndrome. Pediatrics. 1997;99:232-40.

Spuhler-Phillips K, et al. Effects of prenatal ethanol exposure on brain region NMDA-mediated increase in intracellular calcium and the NMDAR1 subunit in forebrain. Alcohol Clin Exp Res. 1997; 21:68-75.

Kirstein CL, et al. Fetal alcohol syndrome: early olfactory learning as a model system to study neurobehavioral deficits. Int J Neurosci. 1997;89:119-32.

Hellstrom A. Fundus morphology assessed by digital image analysis in children with fetal alcohol syndrome. J Pediatr Ophthalmol Strabismus. 1997;34:17-23.

Mattson SN, et al. A decrease in the size of the basal ganglia in children with fetal alcohol syndrome. Alcohol Clin Exp Res. 1996;20:1088-93.

Mattson SN, et al. Heavy prenatal alcohol exposure with or without features of fetal alcohol syndrome leads to IQ deficits. J Pediatr. 1995;131:718-21.

Marin-Garcia J, et al. Mitochondrial dysfunction after fetal alcohol exposure. Alcohol Clin Exp Res. 1996;20:1029-32.

Reyes E, et al. Effects of buthionine sulfoximine on the outcome of the in utero administration of alcohol on fetal development. Alcohol Clin Exp Res. 1996;20:1243-51.

Streissguth AP, et al. Fetal alcohol syndrome in adolescents and adults. JAMA. 1991;265:1961-67.

Sokol RJ, et al. Guidelines for use of terminology describing the impact of prenatal alcohol on the offspring. Alcohol Clin Exp Res. 1989;13:597-98.

Morrow-Tlucak M, et al. Underreporting of alcohol use in pregnancy: relationship to alcohol problem history. Alcohol Clin Exp Res. 1989;13:399-401.

Streissguth AP, et al. Neurobehavioral effects of prenatal alcohol: Part I. Research strategy. Neurotoxicol Teratol. 1989;11:461-76.

Sampson PD, et al. Neurobehavioral effects of prenatal alcohol: Part II. Partial least squares analysis. Neurotoxicol Teratol. 1989;11:477-91.

Streissguth AP, et al. Neurobehavioral effects of prenatal alcohol: Part III. PLS analyses of neuropsychologic tests. Neurotoxicol Teratol. 1989;11:493-507.

Randall CL. Alcohol as a teratogen: a decade of research in review. Alcohol. 1987;Suppl 1:125-32.


Fetal alcohol syndrome


Fetal alcohol syndrome

eMedicine - Gastroschisis -Author: Ali Nawaz Khan, MBBS, LRCP, FRCS, FRCP, FRCR,



National Organization on Fetal Alcohol Syndrome

1200 Eton Court, NW

Third Floor

Washington, DC 20007

Tel: (202)785-4585

Fax: (202)466-6456

Tel: (800)666-6327

Email: information@nofas.org

Internet: http://www.nofas.org

The Arc

1825 K Street NW, Suite 1200

Washington, DC 20006

Tel: (202)534-3700

Fax: (202)534-3731

Tel: (800)433-5255

TDD: (817)277-0553

Email: info@thearc.org

Internet: http://www.thearc.org

Wisconsin Treatment Outreach Project

Univ of WI School of Medicine & Public Health

Dept of Family Medicine,

1100 Delaplaine Court

Madison, WI 53715

Tel: (608)261-1419

Fax: (608)263-5813

Tel: (800)462-5254

Email: WTOP@fammed.wisc.edu

Internet: http://pregnancyandalcohol.org/index.asp?menuID=137&firstlevelmenuID=141

National Mental Health Consumers' Self-Help Clearinghouse

1211 Chestnut Street

Suite 1207

Philadelphia, PA 19107-6312


Tel: (215)751-1810

Fax: (215)636-6312

Tel: (800)553-4539

Email: info@mhselfhelp.org

Internet: http://www.mhselfhelp.org

Mental Health America

2000 N. Beauregard Street, 6th Floor

Alexandria, VA 22314-2971


Tel: (703)684-7722

Fax: (703)684-5968

Tel: (800)969-6642

TDD: (800)433-5959

Email: infoctr@mentalhealthamerica.net

Internet: http://www.mentalhealthamerica.net/

National Alliance on Mental Illness

3803 N. Fairfax Drive

Suite 100

Arlington, VA 22203-

Tel: (703)524-7600

Fax: (703)524-9094

Tel: (800)999-6264

TDD: (703)516-7227

Email: membership@nami.org

Internet: http://www.nami.org

Centers for Disease Control and Prevention

1600 Clifton Road NE

Atlanta, GA 30333

Tel: (404)639-3534

Tel: (800)232-4636

TDD: (888)232-6348

Email: cdcinfo@cdc.gov

Internet: http://www.cdc.gov/

NIH/Institute on Alcohol Abuse and Alcoholism

5635 Fishers Lane

MSC 9304

Bethesda, MD 20892-9304

Tel: (301)443-3860

Fax: (301)443-7043

Email: niaaaweb-r@exchange.nih.gov

Internet: http://www.niaaa.nih.gov/

NIH/National Institute of Mental Health

Health Science Writing, Press and Dissemination Branch

6001 Executive Boulevard

Room 8184, MSC 9663

Bethesda, MD 20892-9663

Tel: (301)443-4513

Fax: (301)443-4279

Tel: (866)615-6464

TDD: (301)443-8431

Email: nimhinfo@nih.gov

Internet: http://www.nimh.nih.gov/index.shtml

Genetic and Rare Diseases (GARD) Information Center

PO Box 8126

Gaithersburg, MD 20898-8126

Tel: (301)251-4925

Fax: (301)251-4911

Tel: (888)205-2311

TDD: (888)205-3223

Internet: http://rarediseases.info.nih.gov/GARD/

Madisons Foundation

PO Box 241956

Los Angeles, CA 90024

Tel: (310)264-0826

Fax: (310)264-4766

Email: getinfo@madisonsfoundation.org

Internet: http://www.madisonsfoundation.org

Perkins School for the Blind

175 North Beacon Street

Watertown, MA 02472

Tel: (617)924-3434

Fax: (617)926-2027

Email: Info@Perkins.org

Internet: http://www.Perkins.org

National Consortium on Deaf-Blindness

The Teaching Research Institute

345 N. Monmouth Avenue

Monmouth, OR 97361

Tel: (800)438-9376

Fax: (503)838-8150

Tel: (800)438-9376

TDD: (800)854-7013

Email: info@nationaldb.org

Internet: http://www.nationaldb.org

Medical Home Portal

Dept. of Pediatrics

University of Utah

P.O. Box 581289

Salt Lake City, UT 84158

Tel: (801)587-9978

Fax: (801)581-3899

Email: mindy.tueller@utah.edu

Internet: http://www.medicalhomeportal.org

For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.